OTC Markets OTCQB - Delayed Quote USD

Northwest Biotherapeutics, Inc. (NWBO)

0.1700 0.0000 (0.00%)

At close: October 30 at 4:00:00 PM EDT

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Northwest Biotherapeutics Announces Expansion of Its Technical Team

PR Newswire 6d ago

NWBO
0.00%
Northwest Biotherapeutics Announces NHSBT Collaboration to Support DCVax-L Production in the UK

InvestorsHub 23d ago

NWBO
0.00%
Northwest Biotherapeutics and the UK National Health Service Blood and Transplant Announce Collaboration to Support DCVax®-L Production

PR Newswire 24d ago

NWBO
0.00%
Northwest Biotherapeutics Highlights Personalized Cancer Vaccine Approach at NHS Oncology Conference

InvestorsHub 26d ago

NWBO
0.00%
Northwest Biotherapeutics Announces Keynote Presentation on Harnessing Immunity: A Personalized, Multi-Target Approach to Cancer At the UK National Health Service Annual Oncology Conference

PR Newswire 26d ago

NWBO
0.00%
Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses

PR Newswire 3mo ago

NWBO
0.00%
Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform

PR Newswire 5mo ago

NWBO
0.00%
Northwest Biotherapeutics: Q3 Earnings Snapshot

Associated Press Finance 11mo ago

NWBO
0.00%
Northwest Biotherapeutics Announces MOU for Collaboration With the Saudi Pharmaceutical Industries and Medical Appliance Company

PR Newswire 2mo ago

NWBO
0.00%
Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting

PR Newswire 3mo ago

NWBO
0.00%
Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic

PR Newswire 6mo ago

NWBO
0.00%
Northwest Biotherapeutics Announces That Construction Activities Are Under Way For the First Grade C Manufacturing Suite in the Sawston, UK Facility

PR Newswire 11mo ago

NWBO
0.00%

Performance Overview

Return	NWBO	S&P 500 (^GSPC)
YTD	-26.09%	+10.73%
1-Year	-29.17%	+11.11%
3-Year	-77.92%	+81.91%

U.S. markets closed

Northwest Biotherapeutics, Inc. (NWBO)

Northwest Biotherapeutics Announces Expansion of Its Technical Team

Northwest Biotherapeutics Announces NHSBT Collaboration to Support DCVax-L Production in the UK

Northwest Biotherapeutics and the UK National Health Service Blood and Transplant Announce Collaboration to Support DCVax®-L Production

Northwest Biotherapeutics Highlights Personalized Cancer Vaccine Approach at NHS Oncology Conference

Northwest Biotherapeutics Announces Keynote Presentation on Harnessing Immunity: A Personalized, Multi-Target Approach to Cancer At the UK National Health Service Annual Oncology Conference

Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses

Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform

Northwest Biotherapeutics: Q3 Earnings Snapshot

Northwest Biotherapeutics Announces MOU for Collaboration With the Saudi Pharmaceutical Industries and Medical Appliance Company

Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting

Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic

Northwest Biotherapeutics Announces That Construction Activities Are Under Way For the First Grade C Manufacturing Suite in the Sawston, UK Facility